ValuentumAd

Official PayPal Seal
Valuentum Reports













Fundamental data is updated weekly, as of the prior weekend. Please download the Full Report and Dividend Report for any changes.
Latest Valuentum Commentary

Mar 23, 2016
What Gilead’s Patent Miscue Means for Shareholders
Image Source: Gilead. Not much…right now, but we’re sleeping better at night not including shares in the newsletter portfolios.
Feb 8, 2016
Market’s Swooning: Bye Bye Energy MLPs, Part II
The broader equity markets remain a very difficult environment.
Feb 1, 2016
Google…Ahem…Alphabet!
We’re still getting used to Google’s new name, but its performance is something we certainly can get used to.
Jan 29, 2016
Alerts: High-grading! GILD-->JNJ; EBAY-->FB
We’re “high-grading” the Best Ideas Newsletter portfolio.
Jan 27, 2016
Giddy Up – It’s Earnings Season!
Let’s cover some recent market news and tackle some recent quarterly releases.
Jan 26, 2016
Johnson & Johnson Reports Strong Underlying Performance
Johnson & Johnson reported solid operational results in 2015. Let’s take a look at the underlying performance of the Dividend Growth Newsletter portfolio holding.
Jan 12, 2016
ICYMI: 5 Concerns About Impending Rate Hikes
The contractionary monetary policy in the US has begun. What to focus on…
Oct 28, 2015
Around the Horn in Biotech/Pharma: 3Q Earnings Review
Abbott, Biogen, Bristol-Myers, Eli Lilly, Gilead, GlaxoSmithKline, Merck, Pfizer…
Oct 26, 2015
If It Happened to AbbVie, Could It Also Happen to Gilead?
Recent news concerning AbbVie’s hepatitis C drugs caused a severe decline in the company’s share price. Could such an event happen to Gilead?
Oct 16, 2015
Johnson & Johnson: A Dividend Growth Gem
Johnson & Johnson continues to grow on an operational basis, and its pharmaceutical pipeline may offer huge rewards in coming years. We’re huge fans of its financial profile and lofty dividend coverage.


Latest News and Media
The High Yield Dividend Newsletter, Best Ideas Newsletter, Dividend Growth Newsletter, Nelson Exclusive publication, and any reports, articles and content found on this website are for information purposes only and should not be considered a solicitation to buy or sell any security. The sources of the data used on this website are believed by Valuentum to be reliable, but the data’s accuracy, completeness or interpretation cannot be guaranteed. Valuentum is not responsible for any errors or omissions or for results obtained from the use of its newsletters, reports, commentary, or publications and accepts no liability for how readers may choose to utilize the content. Valuentum is not a money manager, is not a registered investment advisor and does not offer brokerage or investment banking services. Valuentum, its employees, and affiliates may have long, short or derivative positions in the stock or stocks mentioned on this site.